Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Masimirembwa, CM; Thompson, R; Andersson, TB
   In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery
   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
   
   C.M. Masimirembwa et al., "In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery", COMB CHEM H, 4(3), 2001, pp. 245-263
2. Dubuc, MC; Hamel, C; Caubet, MS; Brazier, JL
   A rapid HPLC-DAD method for separation and determination of omeprazole extracted from human plasma
   JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
   
   M.C. Dubuc et al., "A rapid HPLC-DAD method for separation and determination of omeprazole extracted from human plasma", J LIQ CHR R, 24(8), 2001, pp. 1161-1169
3. Dai, D; Zeldin, DC; Blaisdell, JA; Chanas, B; Coulter, SJ; Ghanayem, BI; Goldstein, JA
   Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
   PHARMACOGENETICS
   
   D. Dai et al., "Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid", PHARMACOGEN, 11(7), 2001, pp. 597-607
4. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Nakagawa, K; Sugimura, H; Ohashi, K; Ishizaki, T
   Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
   PHARMACOGENETICS
   
   T. Furuta et al., "Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin", PHARMACOGEN, 11(4), 2001, pp. 341-348
5. Griese, EU; Ilett, KF; Kitteringham, NR; Eichelbaum, M; Powell, H; Spargo, RM; LeSouef, PN; Musk, AW; Minchin, RF
   Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia
   PHARMACOGENETICS
   
   E.U. Griese et al., "Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia", PHARMACOGEN, 11(1), 2001, pp. 69-76
6. Gerson, LB; Triadafilopoulos, G
   Proton pump inhibitors and their drug interactions: an evidence-based approach
   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
   
   L.B. Gerson e G. Triadafilopoulos, "Proton pump inhibitors and their drug interactions: an evidence-based approach", EUR J GASTR, 13(5), 2001, pp. 611-616
7. Yamada, S; Onda, M; Kato, S; Matsuda, N; Matsuhisa, T; Yamada, N; Miki, M; Matsukura, N
   Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations
   JOURNAL OF GASTROENTEROLOGY
   
   S. Yamada et al., "Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations", J GASTRO, 36(10), 2001, pp. 669-672
8. Sakai, T; Aoyama, N; Kita, T; Sakaeda, T; Nishiguchi, K; Nishitora, Y; Hohda, T; Sirasaka, D; Tamura, T; Tanigawara, Y; Kasuga, M; Okumura, K
   CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects
   PHARMACEUTICAL RESEARCH
   
   T. Sakai et al., "CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects", PHARM RES, 18(6), 2001, pp. 721-727
9. Kita, T; Tanigawara, Y; Aoyama, N; Hohda, T; Saijoh, Y; Komada, F; Sakaeda, T; Okumura, K; Sakai, T; Kasuga, M
   CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability
   PHARMACEUTICAL RESEARCH
   
   T. Kita et al., "CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability", PHARM RES, 18(5), 2001, pp. 615-621
10. Xie, HG; Kim, RB; Wood, AJJ; Stein, CM
    Molecular basis of ethnic differences in drug disposition and response
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    
    H.G. Xie et al., "Molecular basis of ethnic differences in drug disposition and response", ANN R PHARM, 41, 2001, pp. 815-850
11. Goldstein, JA
    Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    J.A. Goldstein, "Clinical relevance of genetic polymorphisms in the human CYP2C subfamily", BR J CL PH, 52(4), 2001, pp. 349-355
12. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
    Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    H.K. Roh et al., "Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients", BR J CL PH, 52(3), 2001, pp. 265-271
13. Yokono, A; Morita, S; Someya, T; Hirokane, G; Okawa, M; Shimoda, K
    The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    A. Yokono et al., "The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients", J CL PSYCH, 21(6), 2001, pp. 549-555
14. Teh, LK; Ismail, R; Yusoff, R; Hussein, A; Isa, MN; Rahman, ARA
    Heterogeneity of the CYP2D6 gene among Malays in Malaysia
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    L.K. Teh et al., "Heterogeneity of the CYP2D6 gene among Malays in Malaysia", J CLIN PH T, 26(3), 2001, pp. 205-211
15. Yao, TW; Zeng, S; Wang, TW; Chen, SQ
    Phenotype analysis of cytochrome P4502C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC
    BIOMEDICAL CHROMATOGRAPHY
    
    T.W. Yao et al., "Phenotype analysis of cytochrome P4502C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC", BIOMED CHRO, 15(1), 2001, pp. 9-13
16. Horai, Y; Kimura, M; Furuie, H; Matsuguma, K; Irie, S; Koga, Y; Nagahama, T; Murakami, M; Matsui, T; Yao, T; Urae, A; Ishizaki, T
    Pharmacodynamic effects and kinetic disposition of rabeprazole in relationto CYP2C19 genotypes
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    Y. Horai et al., "Pharmacodynamic effects and kinetic disposition of rabeprazole in relationto CYP2C19 genotypes", ALIM PHARM, 15(6), 2001, pp. 793-803
17. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
    Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients
    PHARMACOPSYCHIATRY
    
    L.C.W. Lam et al., "Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients", PHARMACOPS, 34(6), 2001, pp. 238-241
18. Hadama, A; Ieiri, I; Morita, T; Kimura, M; Urae, A; Irie, S; Kaneda, T; Mamiya, K; Tashiro, N; Higuchi, S; Otsubo, K
    P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism
    THERAPEUTIC DRUG MONITORING
    
    A. Hadama et al., "P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism", THER DRUG M, 23(2), 2001, pp. 115-118
19. Venkatakrishnan, K; von Moltke, LL; Greenblatt, DJ
    Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    K. Venkatakrishnan et al., "Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models", J CLIN PHAR, 41(11), 2001, pp. 1149-1179
20. Ingelman-Sundberg, M
    Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development
    DRUG METABOLISM AND DISPOSITION
    
    M. Ingelman-Sundberg, "Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development", DRUG META D, 29(4), 2001, pp. 570-573
21. Gerbal-Chaloin, S; Pascussi, JM; Pichard-Garcia, L; Daujat, M; Waechter, F; Fabre, JM; Carrere, N; Maurel, P
    Induction of CYP2C genes in human hepatocytes in primary culture
    DRUG METABOLISM AND DISPOSITION
    
    S. Gerbal-Chaloin et al., "Induction of CYP2C genes in human hepatocytes in primary culture", DRUG META D, 29(3), 2001, pp. 242-251
22. Obach, RS; Zhang, QY; Dunbar, D; Kaminsky, LS
    Metabolic characterization of the major human small intestinal cytochrome P450S
    DRUG METABOLISM AND DISPOSITION
    
    R.S. Obach et al., "Metabolic characterization of the major human small intestinal cytochrome P450S", DRUG META D, 29(3), 2001, pp. 347-352
23. Kosuge, K; Jun, Y; Watanabe, H; Kimura, M; Nishimoto, M; Ishizaki, T; Ohashi, K
    Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamicsof diazepam in relation to CYP2C19 genotype status
    DRUG METABOLISM AND DISPOSITION
    
    K. Kosuge et al., "Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamicsof diazepam in relation to CYP2C19 genotype status", DRUG META D, 29(10), 2001, pp. 1284-1289
24. Furuta, S; Kamada, E; Suzuki, T; Sugimoto, T; Kawabata, Y; Shinozaki, Y; Sano, H
    Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole
    XENOBIOTICA
    
    S. Furuta et al., "Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole", XENOBIOTICA, 31(1), 2001, pp. 1-10
25. Laine, K; Anttila, M; Nyman, L; Wahlberg, A; Bertilsson, L
    CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    K. Laine et al., "CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline", EUR J CL PH, 57(2), 2001, pp. 137-142
26. Furuta, T; Shirai, N; Xiao, F; Ohashi, K; Ishizaki, T
    Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    T. Furuta et al., "Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19", CLIN PHARM, 70(5), 2001, pp. 484-492
27. Wang, JH; Liu, ZQ; Wang, W; Chen, XP; Shu, Y; He, N; Zhou, HH
    Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    J.H. Wang et al., "Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19", CLIN PHARM, 70(1), 2001, pp. 42-47
28. Yu, KS; Yim, DS; Cho, JY; Park, SS; Park, JY; Lee, KH; Jang, IJ; Yi, SY; Bae, KS; Shin, SG
    Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    K.S. Yu et al., "Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19", CLIN PHARM, 69(4), 2001, pp. 266-273
29. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Sugimura, H; Ohashi, K; Ishizaki, T; Kaneko, E
    Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    T. Furuta et al., "Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin", CLIN PHARM, 69(3), 2001, pp. 158-168
30. Ha-Duong, NT; Dijols, S; Macherey, AC; Goldstein, JA; Dansette, PM; Mansuy, D
    Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19
    BIOCHEMISTRY
    
    N.T. Ha-Duong et al., "Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19", BIOCHEM, 40(40), 2001, pp. 12112-12122
31. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
    CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages
    ACTA PSYCHIATRICA SCANDINAVICA
    
    J. Kirchheiner et al., "CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages", ACT PSYC SC, 104(3), 2001, pp. 173-192
32. Zhou, HH; Liu, ZO
    Ethnic differences in drug metabolism
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    
    H.H. Zhou e Z.O. Liu, "Ethnic differences in drug metabolism", CLIN CH L M, 38(9), 2000, pp. 899-903
33. Salsali, M; Coutts, RT; Baker, GB
    A rapid electron-capture gas chromatographic procedure for the analysis ofp-hydroxymephenytoin
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    
    M. Salsali et al., "A rapid electron-capture gas chromatographic procedure for the analysis ofp-hydroxymephenytoin", J PHARM TOX, 44(3), 2000, pp. 461-465
34. Flockhart, DA; Oesterheld, JR
    Cytochrome P450-mediated drug interactions
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    
    D.A. Flockhart e J.R. Oesterheld, "Cytochrome P450-mediated drug interactions", CH ADOLESC, 9(1), 2000, pp. 43
35. Thijssen, HHW; Verkooijen, IWC; Frank, HLL
    The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol
    PHARMACOGENETICS
    
    H.H.W. Thijssen et al., "The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol", PHARMACOGEN, 10(8), 2000, pp. 757-760
36. Roddam, PL; Rollinson, S; Kane, E; Roman, E; Moorman, A; Cartwright, R; Morgan, GJ
    Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia
    PHARMACOGENETICS
    
    P.L. Roddam et al., "Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia", PHARMACOGEN, 10(7), 2000, pp. 605-615
37. Streetman, DS; Bertino, JS; Nafziger, AN
    Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
    PHARMACOGENETICS
    
    D.S. Streetman et al., "Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes", PHARMACOGEN, 10(3), 2000, pp. 187-216
38. Gaedigk, A
    Interethnic differences of drug-metabolizing enzymes
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    A. Gaedigk, "Interethnic differences of drug-metabolizing enzymes", INT J CL PH, 38(2), 2000, pp. 61-68
39. Niwa, T; Tsutsui, M; Kishimoto, K; Yabusaki, Y; Ishibashi, F; Katagiri, M
    Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    T. Niwa et al., "Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A", BIOL PHAR B, 23(4), 2000, pp. 498-501
40. Hiratsuka, M; Agatsuma, Y; Omori, F; Narahara, K; Inoue, T; Kishikawa, Y; Mizugaki, M
    High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5 ' nuclease chain reaction assay
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    M. Hiratsuka et al., "High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5 ' nuclease chain reaction assay", BIOL PHAR B, 23(10), 2000, pp. 1131-1135
41. Wang, XY; Levy, RH; Ho, RJY
    Development of a semi-quantitative assay to detect full-length CYP2C19 RNA
    BIOTECHNIQUES
    
    X.Y. Wang et al., "Development of a semi-quantitative assay to detect full-length CYP2C19 RNA", BIOTECHNIQU, 29(2), 2000, pp. 364
42. Klotz, U
    Pharmacokinetic considerations in the eradication of Helicobacter pylori
    CLINICAL PHARMACOKINETICS
    
    U. Klotz, "Pharmacokinetic considerations in the eradication of Helicobacter pylori", CLIN PHARMA, 38(3), 2000, pp. 243-270
43. Khaliq, Y; Gallicano, K; Seguin, I; Fyke, K; Carignan, G; Bulman, D; Badley, A; Cameron, DW
    Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    Y. Khaliq et al., "Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease", BR J CL PH, 50(2), 2000, pp. 108-115
44. Tassaneeyakul, W; Tassaneeyakul, W; Vannaprasaht, S; Yamazoe, Y
    Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    W. Tassaneeyakul et al., "Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice", BR J CL PH, 49(2), 2000, pp. 139-144
45. Ismail, R; Hussein, A; Teh, LK; Isa, MN
    CYP2D6 phenotypes among Malays in Malaysia
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    R. Ismail et al., "CYP2D6 phenotypes among Malays in Malaysia", J CLIN PH T, 25(5), 2000, pp. 379-383
46. Poolsup, N; Po, ALW; Knight, TL
    Pharmacogenetics and psychopharmacotherapy
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    N. Poolsup et al., "Pharmacogenetics and psychopharmacotherapy", J CLIN PH T, 25(3), 2000, pp. 197-220
47. Sagar, M; Bertilsson, L; Stridsberg, M; Kjellin, A; Mardh, S; Seensalu, R
    Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    M. Sagar et al., "Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders", ALIM PHARM, 14(11), 2000, pp. 1495-1502
48. Adachi, K; Katsube, T; Kawamura, A; Takashima, T; Yuki, M; Amano, K; Ishihara, S; Fukuda, R; Watanabe, M; Kinoshita, Y
    CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    K. Adachi et al., "CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole", ALIM PHARM, 14(10), 2000, pp. 1259-1266
49. Egan, LJ; Murray, JA
    New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors
    DIGESTIVE DISEASES
    
    L.J. Egan e J.A. Murray, "New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors", DIGEST DIS, 18(2), 2000, pp. 58-63
50. Shu, Y; Wang, LS; Xiao, WM; Wang, W; Huang, SL; Zhou, HH
    Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone
    ACTA PHARMACOLOGICA SINICA
    
    Y. Shu et al., "Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone", ACT PHAR SI, 21(8), 2000, pp. 753-758
51. Shu, Y; Zhou, HH
    Individual and ethnic differences in CYP2C19 activity in Chinese populations
    ACTA PHARMACOLOGICA SINICA
    
    Y. Shu e H.H. Zhou, "Individual and ethnic differences in CYP2C19 activity in Chinese populations", ACT PHAR SI, 21(3), 2000, pp. 193-199
52. Eap, CB; Bertel-Laubscher, R; Zullino, D; Amey, M; Baumann, P
    Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report
    PHARMACOPSYCHIATRY
    
    C.B. Eap et al., "Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report", PHARMACOPS, 33(3), 2000, pp. 112-115
53. Houston, JB; Kenworthy, KE
    In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
    DRUG METABOLISM AND DISPOSITION
    
    J.B. Houston e K.E. Kenworthy, "In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model", DRUG META D, 28(3), 2000, pp. 246-254
54. Wester, MR; Lasker, JM; Johnson, EF; Raucy, JL
    CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
    DRUG METABOLISM AND DISPOSITION
    
    M.R. Wester et al., "CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes", DRUG META D, 28(3), 2000, pp. 354-359
55. McGinnity, DF; Parker, AJ; Soars, M; Riley, RJ
    Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s
    DRUG METABOLISM AND DISPOSITION
    
    D.F. McGinnity et al., "Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s", DRUG META D, 28(11), 2000, pp. 1327-1334
56. Renwick, AB; Surry, D; Price, RJ; Lake, BG; Evans, DC
    Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms
    XENOBIOTICA
    
    A.B. Renwick et al., "Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms", XENOBIOTICA, 30(10), 2000, pp. 955-969
57. Wedlund, PJ
    The CYP2C19 enzyme polymorphism
    PHARMACOLOGY
    
    P.J. Wedlund, "The CYP2C19 enzyme polymorphism", PHARMACOL, 61(3), 2000, pp. 174-183
58. Fukuda, T; Nishida, Y; Zhou, Q; Yamamoto, I; Kondo, S; Azuma, J
    The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    T. Fukuda et al., "The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population", EUR J CL PH, 56(2), 2000, pp. 175-180
59. Mamiya, K; Hadama, A; Yukawa, E; Ieiri, I; Otsubo, K; Ninomiya, H; Tashiro, N; Higuchi, S
    CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    K. Mamiya et al., "CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics", EUR J CL PH, 55(11-12), 2000, pp. 821-825
60. Shu, Y; Wang, LS; Xu, ZH; He, N; Xiao, WM; Wang, W; Huang, SL; Zhou, HH
    5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    Y. Shu et al., "5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity", J PHARM EXP, 295(2), 2000, pp. 844-851
61. Sagar, M; Tybring, G; Dahl, ML; Bertilsson, L; Seensalu, R
    Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
    GASTROENTEROLOGY
    
    M. Sagar et al., "Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism", GASTROENTY, 119(3), 2000, pp. 670-676
62. Streetman, DS; Bleakley, JF; Kim, JS; Nafziger, AN; Leeder, JS; Gaedigk, A; Gotschall, R; Kearns, GL; Bertino, JS
    Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail"
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    D.S. Streetman et al., "Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail"", CLIN PHARM, 68(4), 2000, pp. 375-383
63. Branch, RA; Adedoyin, A; Frye, RF; Wilson, JW; Romkes, M
    In vivo modulation of CYP enzymes by quinidine and rifampin
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    R.A. Branch et al., "In vivo modulation of CYP enzymes by quinidine and rifampin", CLIN PHARM, 68(4), 2000, pp. 401-411
64. Lamba, JK; Dhiman, RK; Kohli, KK
    CYP2C19 genetic mutations in North Indians
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    J.K. Lamba et al., "CYP2C19 genetic mutations in North Indians", CLIN PHARM, 68(3), 2000, pp. 328-335
65. Laine, K; Tybring, G; Bertilsson, L
    No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    K. Laine et al., "No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects", CLIN PHARM, 68(2), 2000, pp. 151-159
66. Herrlin, K; Massele, AY; Rimoy, G; Alm, C; Rais, M; Ericsson, O; Bertilsson, L; Gustafsson, LL
    Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    K. Herrlin et al., "Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype", CLIN PHARM, 68(2), 2000, pp. 189-198
67. Furuta, T; Takashima, M; Shirai, N; Xiao, F; Hanai, H; Ohashi, K; Ishizaki, T
    Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    T. Furuta et al., "Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient", CLIN PHARM, 67(6), 2000, pp. 684-689
68. Yoon, YR; Cha, IJ; Shon, JH; Lim, KA; Cha, YN; Jang, IJ; Park, CW; Shin, SG; Flockhart, DA; Shin, JG
    Relationship of paroxetine disposition to metoprolol metabolic ratio and CPsi P2D6*10 genotype of Korean subjects
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    Y.R. Yoon et al., "Relationship of paroxetine disposition to metoprolol metabolic ratio and CPsi P2D6*10 genotype of Korean subjects", CLIN PHARM, 67(5), 2000, pp. 567-576
69. Ho, SL; Kung, MHW; Li, LSW; Lauder, IJ; Ramsden, DB
    Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease inChinese and Caucasians
    EUROPEAN JOURNAL OF NEUROLOGY
    
    S.L. Ho et al., "Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease inChinese and Caucasians", EUR J NEUR, 6(3), 1999, pp. 323-329
70. Linder, MW; Valdes, R
    Pharmacogenetics in the practice of laboratory medicine
    MOLECULAR DIAGNOSIS
    
    M.W. Linder e R. Valdes, "Pharmacogenetics in the practice of laboratory medicine", MOL DIAGN, 4(4), 1999, pp. 365-379
71. Wennerholm, A; Johansson, I; Massele, AY; Jande, M; Alm, C; Aden-Abdi, Y; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L; Gustafsson, LL
    Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
    PHARMACOGENETICS
    
    A. Wennerholm et al., "Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype", PHARMACOGEN, 9(6), 1999, pp. 707-714
72. Xie, HG; Stein, CM; Kim, RB; Wilkinson, GR; Flockhart, DA; Wood, AJJ
    Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
    PHARMACOGENETICS
    
    H.G. Xie et al., "Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world", PHARMACOGEN, 9(5), 1999, pp. 539-549
73. Kaneko, A; Lum, JK; Yaviong, J; Takahashi, N; Ishizaki, T; Bertilsson, L; Kobayakawa, T; Bjorkman, A
    High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands
    PHARMACOGENETICS
    
    A. Kaneko et al., "High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands", PHARMACOGEN, 9(5), 1999, pp. 581-590
74. Kaneko, A; Bergqvist, Y; Taleo, G; Kobayakawa, T; Ishizaki, T; Bjorkman, A
    Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations
    PHARMACOGENETICS
    
    A. Kaneko et al., "Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations", PHARMACOGEN, 9(3), 1999, pp. 317-326
75. Griese, EU; Lapple, F; Eichelbaum, M
    Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction
    PHARMACOGENETICS
    
    E.U. Griese et al., "Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction", PHARMACOGEN, 9(3), 1999, pp. 389-391
76. Rost, KL; Fuhr, U; Thomsen, T; Zaigler, M; Brockmoller, J; Bohnemeier, H; Roots, I
    Omeprazole weakly inhibits CYP1A2 activity in man
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    K.L. Rost et al., "Omeprazole weakly inhibits CYP1A2 activity in man", INT J CL PH, 37(11), 1999, pp. 567-574
77. Masa, K; Arimori, K; Nakayama, T; Miyamoto, S; Fujii, J; Nakano, M
    Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    K. Masa et al., "Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs", BIOL PHAR B, 22(5), 1999, pp. 504-509
78. Damkier, P; Hansen, LL; Brosen, K
    Rifampicin treatment greatly increases the apparent oral clearance of quinidine
    PHARMACOLOGY & TOXICOLOGY
    
    P. Damkier et al., "Rifampicin treatment greatly increases the apparent oral clearance of quinidine", PHARM TOX, 85(6), 1999, pp. 257-262
79. Payne, VA; Chang, YT; Loew, GH
    Homology modeling and substrate binding study of human CYP2C9 enzyme
    PROTEINS-STRUCTURE FUNCTION AND GENETICS
    
    V.A. Payne et al., "Homology modeling and substrate binding study of human CYP2C9 enzyme", PROTEINS, 37(2), 1999, pp. 176-190
80. Payne, VA; Chang, YT; Loew, GH
    Homology modeling and substrate binding study of human CYP2C18 and CYP2C19enzymes
    PROTEINS-STRUCTURE FUNCTION AND GENETICS
    
    V.A. Payne et al., "Homology modeling and substrate binding study of human CYP2C18 and CYP2C19enzymes", PROTEINS, 37(2), 1999, pp. 204-217
81. Mihara, K; Svensson, USH; Tybring, G; Hai, TN; Bertilsson, L; Ashton, M
    Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
    FUNDAMENTAL & CLINICAL PHARMACOLOGY
    
    K. Mihara et al., "Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19", FUN CL PHAR, 13(6), 1999, pp. 671-675
82. Bathum, L; Skjelbo, E; Mutabingwa, TK; Madsen, H; Horder, M; Brosen, K
    Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    L. Bathum et al., "Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population", BR J CL PH, 48(3), 1999, pp. 395-401
83. Xie, HG; Kim, RB; Stein, CM; Wilkinson, GR; Wood, AJJ
    Genetic polymorphism of (S)-mephenytoin 4 '-hydroxylation in populations of African descent
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    H.G. Xie et al., "Genetic polymorphism of (S)-mephenytoin 4 '-hydroxylation in populations of African descent", BR J CL PH, 48(3), 1999, pp. 402-408
84. Aynacioglu, AS; Brockmoller, J; Bauer, S; Sachse, C; Guzelbey, P; Ongen, Z; Nacak, M; Roots, I
    Frequency of cytochrome P450CYP2C9 variants in a Turkish population and functional relevance for phenytoin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    A.S. Aynacioglu et al., "Frequency of cytochrome P450CYP2C9 variants in a Turkish population and functional relevance for phenytoin", BR J CL PH, 48(3), 1999, pp. 409-415
85. Coller, JK; Somogyi, AA; Bochner, F
    Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    J.K. Coller et al., "Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms", BR J CL PH, 48(2), 1999, pp. 158-167
86. Brynne, N; Bottiger, Y; Hallen, B; Bertilsson, L
    Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    N. Brynne et al., "Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole", BR J CL PH, 47(2), 1999, pp. 145-150
87. Kimura, M; Ieiri, I; Wada, Y; Mamiya, K; Urae, A; Iimori, E; Sakai, T; Otsubo, K; Higuchi, S
    Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping:possible effect of age, liver disease and length of therapy
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    M. Kimura et al., "Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping:possible effect of age, liver disease and length of therapy", BR J CL PH, 47(1), 1999, pp. 115-119
88. Cohen, LG; Prince, J; Biederman, J; Wilens, T; Faraone, SV; Whitt, S; Mick, E; Spencer, T; Meyer, MC; Polisner, D; Flood, JG
    Absence of effect of stimulants on the pharmacokinetics of desipramine in children
    PHARMACOTHERAPY
    
    L.G. Cohen et al., "Absence of effect of stimulants on the pharmacokinetics of desipramine in children", PHARMACOTHE, 19(6), 1999, pp. 746-752
89. Coutts, RT; Urichuk, LJ
    Polymorphic cytochromes P450 and drugs used in psychiatry
    CELLULAR AND MOLECULAR NEUROBIOLOGY
    
    R.T. Coutts e L.J. Urichuk, "Polymorphic cytochromes P450 and drugs used in psychiatry", CELL MOL N, 19(3), 1999, pp. 325-354
90. Shimoda, K; Jerling, M; Bottiger, Y; Yasuda, S; Morita, S; Bertilsson, L
    Pronounced differences in the disposition of clomipramine between Japaneseand Swedish patients
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    K. Shimoda et al., "Pronounced differences in the disposition of clomipramine between Japaneseand Swedish patients", J CL PSYCH, 19(5), 1999, pp. 393-400
91. Tanaka, E
    Update: genetic polymorphism of drug metabolizing enzymes in humans
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    E. Tanaka, "Update: genetic polymorphism of drug metabolizing enzymes in humans", J CLIN PH T, 24(5), 1999, pp. 323-329
92. Tanaka, E
    Clinically significant pharmacokinetic drug interactions with benzodiazepines
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    E. Tanaka, "Clinically significant pharmacokinetic drug interactions with benzodiazepines", J CLIN PH T, 24(5), 1999, pp. 347-355
93. Tanaka, E
    Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    E. Tanaka, "Clinically significant pharmacokinetic drug interactions between antiepileptic drugs", J CLIN PH T, 24(2), 1999, pp. 87-92
94. Tanaka, E; Hisawa, S
    Clinically significant pharmacokinetic drug interactions with psychoactivedrugs: antidepressants and antipsychotics and the cytochrome P450 system
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    E. Tanaka e S. Hisawa, "Clinically significant pharmacokinetic drug interactions with psychoactivedrugs: antidepressants and antipsychotics and the cytochrome P450 system", J CLIN PH T, 24(1), 1999, pp. 7-16
95. Sagar, M; Janczewska, I; Ljungdahl, A; Bertilsson, L; Seensalu, R
    Effect of CYP2C19 polymorphism on serum levels of vitamin B-12 in patientson long-term omeprazole treatment
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    M. Sagar et al., "Effect of CYP2C19 polymorphism on serum levels of vitamin B-12 in patientson long-term omeprazole treatment", ALIM PHARM, 13(4), 1999, pp. 453-458
96. Lew, EA
    Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    E.A. Lew, "Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy", ALIM PHARM, 13, 1999, pp. 11-16
97. Ishizaki, T; Horai, Y
    Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    T. Ishizaki e Y. Horai, "Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole", ALIM PHARM, 13, 1999, pp. 27-36
98. Kovacs, P; Edwards, DJ; Lalka, D; Scheiwe, WM; Stoeckel, K
    High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping
    THERAPEUTIC DRUG MONITORING
    
    P. Kovacs et al., "High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping", THER DRUG M, 21(5), 1999, pp. 526-531
99. Kobayashi, K; Ishizuka, T; Shimada, N; Yoshimura, Y; Kamijima, K; Chiba, K
    Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro
    DRUG METABOLISM AND DISPOSITION
    
    K. Kobayashi et al., "Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro", DRUG META D, 27(7), 1999, pp. 763-766
100. Nakajima, M; Nakamura, S; Tokudome, S; Shimada, N; Yamazaki, H; Yokoi, T
     Azelastine N-demethylation by cytochrome P-450 (CYP) 3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPS
     DRUG METABOLISM AND DISPOSITION
     
     M. Nakajima et al., "Azelastine N-demethylation by cytochrome P-450 (CYP) 3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPS", DRUG META D, 27(12), 1999, pp. 1381-1391